Eli Lilly and Company (LLY) recently became the first healthcare company to reach a market capitalization exceeding $1 trillion, marking a historic milestone in the industry. This achievement is deeply rooted in its exceptional performance over the past few years, and its development prospects for the coming year are equally compelling. The company’s growth potential is primarily driven by its robust research and development pipeline and ongoing market expansion.
Lilly has established a leadership position in the anti-obesity drug sector, and the expected launch of two new drugs in 2026 is set to further solidify its advantage. The first is the oral GLP-1 receptor agonist orforglipron, which has demonstrated outstanding results in Phase 3 clinical trials for weight management and type 2 diabetes. Not only does it effectively reduce body weight and lower HbA1c levels, but it has also outperformed some of its peers in head-to-head studies. Thanks to the U.S. Food and Drug Administration’s (FDA) “fast-track” policy, the approval timeline for this drug could be significantly shortened from the typical 10 to 12 months, potentially gaining approval as early as 2026.
Another potential blockbuster is retatrutide. Its uniqueness lies in mimicking the effects of three intestinal hormones, making it the first triple-hormone pathway therapy. Later-stage studies indicate that the highest dose can achieve an average weight loss of 28.7%, positioning it as an industry leader in efficacy data. This drug targets unmet needs among individuals with higher body mass indices who have not responded well to existing treatments and is expected to be approved by the end of 2026. The FDA’s fast-track approval program addresses public health issues such as obesity, and retatrutide may also qualify for accelerated review. If it receives positive data and authorization, it will provide Lilly with new growth momentum.
The market anticipates that Lilly may announce a stock split in 2026. The company’s last stock split dates back to the late 1990s, and its current stock price has reached a high level of around $1,000. While a stock split does not directly impact the company’s fundamentals, it is often seen as a signal of management’s confidence in the company’s medium-term prospects. With strong revenue and profit growth and a rich pipeline of drugs in development, Lilly’s stock price could rise further if its growth trajectory continues. A stock split could help enhance stock liquidity and attract a broader range of investors.
Despite facing increasing competition in its core therapeutic areas, Lilly maintains advantages in its mid- to late-stage clinical trial results. Additionally, the company has a diversified portfolio of approved drugs and projects in other areas, such as Kisunla for Alzheimer’s disease, the cancer drug Verzenio, and immunology drugs Omvoh and Taltz, all of which contribute to its business resilience. In terms of valuation, Lilly’s forward price-to-earnings ratio is approximately 32x, higher than the healthcare sector average of 17.8x. However, its revenue and profit growth rates are sufficient to justify this premium. Market performance indicates that investors remain optimistic about the long-term return potential of Lilly’s stock, and recent stock price movements reflect positive expectations regarding the accelerated approval process for its new drugs.
